Lantern Pharma Inc — Balance Sheet (NASDAQ:LTRN) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 20.36 M73.95 M58.84 M43.65 M25.57 M Total liabilities 660.84 K2.38 M2.8 M2.74 M4.38 M Total equity 19.7 M71.57 M56.04 M40.91 M21.19 M Total liabilities & shareholders' equities 20.36 M73.95 M58.84 M43.65 M25.57 M Total debt ————— Net debt —————

Nachrichten

Lantern Pharma: FDA erteilt Orphan-Drug-Status für Sarkom-Medikament LP-284

FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas

Lantern Pharma: Krebsmedikament LP-184 zeigt vielversprechende Ergebnisse in Phase-1a-Studie

Lantern’s cancer drug LP-184 shows promise in phase 1a trial

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2025-11-15

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Disney, Brookfield, Nu Holdings and more set to report earnings Thursday

Lantern Pharma: Aktionäre wählen Direktoren und stimmen Neufestsetzung von Aktienoptionen zu

Lantern Pharma shareholders elect directors and approve stock option repricing

Lantern Pharma: Aktie legt nach erfolgreicher Studie zu Krebsmedikament LP-184 zu

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints